Resection and reconstruction for periacetabular tumors is one of the most difficult challenges for the orthopedic oncologist. The primary goal of the procedure is to control the tumor locally by complete resection. The secondary goal is to reconstruct the periacetabular defect to restore as much pelvic stability and hip joint function as possible. Reconstructive options after periacetabular resection can be divided into 2 categories depending on the preservation of the acetabular-femoral articulation. Nonpreservation reconstruction includes fusion, saddle prosthesis insertion, hip transposition, and pseudoarthrosis.\(^1\) Preservation reconstruction includes the use of a custom-made prosthesis and allograft or recycled autograft-prosthesis composite.\(^2\) When internal pelvectomy was introduced as an alternative to hindquarter amputation, iliofemoral coaptation or ischiofemoral arthrodesis was performed with the compromise of limb length shortening and hip instability.\(^2,3\) The use of a saddle prosthesis was considered a temporary compromise to address the issue of flail hip; however, this prosthesis posed the risk of cranialization or luxation of the implant.\(^4,5\) Therefore, to achieve pelvic continuity and durable hip function, acetabular-femoral articulation-preserving reconstruction was devised.\(^6,11,14-16\) This provided promising results in a substantial proportion of patients, but short- and long-term complications were significant.\(^6,17-19\) In this regard, pseudoarthrosis or hip transposition, which may avoid problems related to

**Background:** Because of the high complication rate of anatomical reconstruction after periacetabular resection, the strategy of resection alone has been revisited. However, in terms of complications and functional outcome, whether resection hip arthroplasty (RHA) shows a superior result to that of pelvic ring reconstruction remains controversial.

**Methods:** We compared 24 RHAs and 16 pasteurized autograft-prosthesis composite (PPC) reconstructions regarding the complication rates, operative time, blood loss, and functional outcome.

**Results:** Compared to 16 PPC hips, 24 RHA hips showed lower major and minor complication rates (\(p < 0.001\)), shorter surgical time (\(p < 0.001\)), and superior Musculoskeletal Tumor Society scores (\(p < 0.001\)). Of the 24 RHA hips, bony neo-acetabulum was identified in 7 on computed tomography and partial neo-acetabulum in 9; the remaining 8 had no bony acetabular structure. The average time to bony neo-acetabulum formation was 7 months (range, 4 to 13 months).

**Conclusions:** RHA for periacetabular tumors can be an excellent alternative to anatomical reconstruction. It offers short surgical time, low complication rates, and functional results comparable to those of other reconstruction methods. However, this procedure is indicated for patients who can accept some limb shortening, and a tumor should be confined to the periacetabular area.

**Keywords:** Acetabulum, Reconstructive surgery, Treatment outcome
pelvic ring reconstruction, is being revisited.\textsuperscript{1,20-22} A recent report of resection hip arthroplasty (RHA) in 27 patients has reconfirmed the usefulness of this approach, a similar technique of which was addressed in a study involving 5 patients in 1978.\textsuperscript{2,23} Hu et al.\textsuperscript{23} postulated that RHA would show fewer complications, shorter surgical time, less blood loss, and better functional results than those of pelvic ring reconstruction methods. However, in terms of complications and functional outcomes, whether RHA is superior to anatomical pelvic ring reconstruction is still controversial. Proponents of anatomical reconstruction speculate that functional results in patients with failed pelvic ring reconstruction would not be inferior to those of primary RHA.

In this study, we compared the results of 24 cases of RHA and 16 pasteurized bone-prosthesis composite reconstructions in terms of complication rates, operative time, blood loss, and ultimate functional outcome. Addi-

| Case | Age (yr)/sex | Diagnosis | Tumor stage | TV (cc) | Extent of iliac lesion (cm) | Resection type | Surgical margin | Surgical time (hr) | RBC transfusion (pint)* | LR | Meta. | Final status | F/U (mo) |
|------|--------------|-----------|-------------|--------|---------------------------|---------------|----------------|------------------|-----------------------------|----|-------|--------------|--------|
| 1    | 21/F         | GCT       | Benign      | 115    | 2.3                       | II            | m              | 2.2              | 7                           | +  | -     | NED          | 54     |
| 2    | 17/F         | OS        | IIIB        | 145    | 1.2                       | II + III      | w              | 4.8              | 1                           | -  | -     | CDF          | 70     |
| 3    | 17/F         | CS        | IIIB        | 648    | 1                        | II + III      | w              | 4.8              | 10                          | -  | -     | CDF          | 182    |
| 4    | 32/M         | GCT       | Benign      | 66     | 0                         | II + III\textsuperscript{†} | m              | 2.7              | 2                           | +  | -     | NED          | 118    |
| 5    | 43/F         | FS        | IIIB        | 111    | 1.7                       | II + III      | w              | 3.9              | 4                           | +  | -     | DOD          | 41     |
| 6    | 47/F         | CS        | IIIB        | 172    | 0                         | II + III      | w              | 5.1              | 2                           | -  | -     | CDF          | 61     |
| 7    | 68/M         | CS        | IIIB        | 103    | 2.5                       | II + III      | m              | 4.8              | 11                          | +  | -     | AWD          | 66     |
| 8    | 34/M         | CS        | IIIB        | 66     | 4.5                       | I\textsuperscript{†} + II | w              | 1.8              | 2                           | -  | -     | CDF          | 37     |
| 9    | 43/M         | CS        | IIIB        | 165    | 4.9                       | I\textsuperscript{†} + II | w              | 1.7              | 0                           | -  | -     | CDF          | 35     |
| 10   | 46/M         | CS        | IIA         | 87     | 3.7                       | I\textsuperscript{†} + II | w              | 2.0              | 0                           | -  | -     | CDF          | 32     |
| 11   | 47/M         | CS        | IIA         | 67     | 3.4                       | I\textsuperscript{†} + II | w              | 1.7              | 3                           | -  | -     | CDF          | 29     |
| 12   | 15/M         | SS        | III         | 165    | 1.7                       | I\textsuperscript{†} + II + III | m              | 2.7              | 4                           | -  | -     | CDF          | 37     |
| 13   | 21/M         | SS        | III         | 147    | 2.5                       | I\textsuperscript{†} + II + III | m              | 4.7              | 9                           | -  | -     | CDF          | 280    |
| 14   | 22/M         | OS        | IIIB        | 330    | 0.9                       | I\textsuperscript{†} + II + III | w              | 8.8              | 12                          | -  | -     | CDF          | 69     |
| 15   | 27/M         | OS        | IIIB        | 125    | 3.3                       | I\textsuperscript{†} + II + III | m              | 5.4              | 7                           | -  | -     | CDF          | 43     |
| 16   | 30/M         | GCT       | Benign      | 144    | 5                         | I\textsuperscript{†} + II + III\textsuperscript{†} | w              | 5.5              | 10                          | -  | -     | CDF          | 132    |
| 17   | 32/M         | OS        | IIIB        | 204    | 2.2                       | I\textsuperscript{†} + II + III | w              | 5.0              | 11                          | -  | -     | CDF          | 26     |
| 18   | 34/F         | CS        | IIIB        | 414    | 2                        | I\textsuperscript{†} + II + III | w              | 5.8              | 8                           | -  | -     | CDF          | 301    |
| 19   | 36/F         | OS        | IIIB        | 383    | 4.4                       | I\textsuperscript{†} + II + III | m              | 5.2              | 20                          | +  | +     | DOD          | 36     |
| 20   | 39/M         | CS        | IIIB        | 116    | 0                         | I\textsuperscript{†} + II + III | w              | 5.1              | 4                           | -  | -     | CDF          | 56     |
| 21   | 41/M         | CS        | IIIB        | 212    | 3.4                       | I\textsuperscript{†} + II + III | m              | 2.9              | 6                           | +  | +     | NED          | 26     |
| 22   | 46/M         | CS        | IIIB        | 725    | 8                         | I\textsuperscript{†} + II + III | i              | 3.5              | 12                          | +  | -     | NED          | 42     |
| 23   | 61/M         | CS        | IIIB        | 565    | 1.6                       | I\textsuperscript{†} + II + III | m              | 5.9              | 15                          | -  | -     | CDF          | 35     |
| 24   | 65/M         | CS        | IIIB        | 162    | 3.4                       | I\textsuperscript{†} + II + III | w              | 5.5              | 5                           | -  | -     | CDF          | 69     |

TV: tumor volume, iliac lesion: measured from the top of the femoral head, RBC: red blood cell, LR: local recurrence, Meta.: metastasis, GCT: giant cell tumor, m: marginal, +: local recurrence confirmed, NED: no evidence of disease, OS: osteosarcoma, w: wide, CDF: continuous disease-free, CS: chondrosarcoma, FS: fibrosarcoma, DOD: died of disease, AWD: alive with disease, SS: synovial sarcoma, i: intrajesotal.

*RBC 1 pint: 400 cc. Partial resection of involved bone.
tionally, in cases of RHA, we described the pattern of neo-
hip joint formation according to the extent of iliac bone
resection or the mode of postoperative management.

**METHODS**

Between January 1990 and March 2015, 99 patients with
pelvic bone and soft tissue tumors underwent periacetabular
resection at Korea Cancer Center Hospital. According
to the pelvic resection category described by Enneking and
Dunham, 12 43 were type I + II, 28 were type I + II + III,
25 were type II + III, and 3 were type II resections. Among
these, we selected 24 patients who underwent RHA and 16
patients who underwent pasteurized autograft-prosthesis
composite (PPC) reconstruction. Exclusion criteria were:
(1) iliac resection at the sacroiliac joint (37 patients); (2)
reconstruction with saddle prosthesis (8 patients); and
(3) less than 2 years of follow-up without an event (14
patients). Finally, 23 male and 17 female patients with an
average age of 35.3 years (range, 15 to 68 years) were in-
cluded. Follow-up duration was a minimum of 13 months
(average, 101 months; range, 13 to 301 months).

The criteria for RHA were: (1) tumors located
mainly in region II and III (some partially involved region
I) and (2) preoperative magnetic resonance imaging (MRI)
showing no sign of femoral head involvement by tumor.
PPC reconstruction was indicated for tumors when at least
1 of 2 landmarks on plain pelvic anteroposterior radiographs
(ilioischial and iliopectineal lines) was intact.

Of the 24 patients who underwent RHA, 18 had pri-
mary malignant bone tumors, 3 had soft tissue sarcomas,
and 3 had giant cell tumors (Table 1). Of the 16 patients
who underwent PPC reconstruction, 11 had primary
malignant bone tumors, 3 had benign aggressive bone tu-
mors, and 2 had metastatic tumors (Table 2). Preoperative
staging included plain radiography and MRI of the pelvis,
computed tomography (CT) of the chest, and whole body
technetium bone scan. Staging was determined accord-

---

### Table 2. Demographic Data of 16 Patients with Pasteurized Autograft-Prosthesis Composite Reconstruction

| Case | Age (yr)/sex | Diagnosis | Tumor stage | TV (cc) | Resection type | Surgical margin | Surgical time (hr) | RBC transfusion (pint)* | LR | Meta. | Final status | F/U (mo) |
|------|--------------|-----------|-------------|--------|---------------|----------------|-------------------|-----------------------|----|-------|-------------|---------|
| 1    | 35/M         | OS        | IIB         | 52     | II            | w              | 7                 | 6                     |    | +     | DOD         | 24      |
| 2    | 19/F         | GCT       | Benign      | 188    | II + III      | w              | 5.8               | 8                     |    | -     | CDF         | 271     |
| 3    | 20/F         | OS        | IB          | 63     | II + III      | m              | 7                 | 7                     |    | -     | CDF         | 246     |
| 4    | 49/F         | HES       | IB          | 187    | II + III      | w              | 6.4               | 6                     |    | -     | CDF         | 243     |
| 5    | 52/M         | CS        | IIB         | 251    | II + III      | w              | 8                 | 9                     |    | -     | CDF         | 125     |
| 6    | 54/F         | CS        | IIB         | 110    | II + III      | w              | 6.3               | 9                     |    | -     | CDF         | 108     |
| 7    | 18/F         | ES        | IIB         | 201    | I + II        | m              | 7.3               | 7                     | + | -     | DOD         | 13      |
| 8    | 20/F         | OS        | IIB         | 377    | I + II        | m              | 7.6               | 16                    |    | -     | CDF         | 150     |
| 9    | 21/M         | MFH       | IIB         | 31     | I + II        | w              | 7.3               | 5                     |    | -     | CDF         | 254     |
| 10   | 24/F         | DF        | Benign      | 82     | I + II        | m              | 6.8               | 9                     |    | -     | CDF         | 120     |
| 11   | 34/F         | MC        | III         | 79     | I + II        | w              | 7.9               | 13                    | + | -     | NED         | 224     |
| 12   | 54/F         | MC        | III         | 26     | I + II        | w              | 6.6               | 7                     |    | -     | CDF         | 161     |
| 13   | 25/M         | CS        | IIB         | 653    | I + II + I + III | m     | 9.3               | 15                    |    | -     | CDF         | 141     |
| 14   | 30/M         | OS        | IIB         | 226    | I + II + III  | w              | 7.3               | 4                     | + | +    | DOD         | 69      |
| 15   | 31/F         | CS        | IIB         | 63     | I + II + I + III | w     | 6.8               | 8                     |    | -     | CDF         | 63      |
| 16   | 45/M         | CS        | IIB         | 141    | I + II + I + III | w     | 7.3               | 10                    | + | +    | DOD         | 21      |

TV: tumor volume, RBC: red blood cell, LR: local recurrence, Meta.: metastasis, OS: osteosarcoma, w: wide, +: local recurrence confirmed, DOD: died of disease, GCT: giant cell tumor, CDF: continuous disease-free, m: marginal, HES: hemangiendothelioma, CS: chondrosarcoma, ES: Ewing sarcoma, MFH: malignant fibrous histiocytoma, DF: desmoplastic fibrosarcoma, MC: metastatic carcinoma, NED: no evidence of disease.

*RBC 1 pint: 400 cc. Partial resection of involved bone.
Neoadjuvant and adjuvant chemotherapy were administered to 13 patients. Initial tumor volume, pathologic diagnosis, extent of iliac lesion on MRI, osteotomy level from iliac crest, resection type, surgical time, surgical margin, and amount of transfusion were recorded. The tumor volume was calculated using 3 parameters (height, width, and depth) by the ellipsoid formula: \[ V = \frac{4\pi}{3} \times a \times b \times c. \] The height, width, and depth of a tumor were measured on the coronal and axial plane MRI scans. The resection and reconstruction included the following procedures. An ilioinguinal approach was used for the main incision, and a satellite incision was made from the anterosuperior iliac spine to the greater trochanter, if necessary. In 12 of the 24 patients who underwent RHA, 2 or 3 osteotomies were made to preserve the iliac bone-hip flexor or abductor continuity, and to displace the bone block-muscle complex inferiorly and laterally. Pelvic resection was classified according to the system of Enneking and Dunham. In 16 cases of PPC reconstruction, 6 cases were type I + II, 5 were type II + III, 4 were type I + II + III, and 1 was a type II resection. In 24 cases of RHA, 13 were type I + II + III, 6 were type II + III, 4 were type I + II, and 1 was a type II resection. The margin in the 40 patients was wide in 25, marginal in 14, and intralesional in 1, according to Enneking’s criteria. The preparation of pasteurized bone and reconstruction using a total hip prosthesis was performed as described previously. In RHA, the average osteotomy length from the iliac crest was 9.5 cm (range, 4 to 14.5 cm). After tumor removal, the femoral head was pushed up to the inferior aspect of the resected ilium. In 12 cases, the femoral head was fixed to the remaining ilium with wire. In the remaining 12 cases, no fixation was undertaken. In 12 cases of RHA, previously detached iliac bone block-muscle complex was repositioned to the iliac wing with wire. Postoperatively, patients who underwent PPC reconstruction were usually immobilized for 8–10 weeks in a one-and-a-half hip spica cast, which was followed by crutch walking until radiographic union was achieved. In patients who underwent RHA, only 3 were immobilized in a hip spica cast. The remaining 21 were allowed to ambulate when drains were removed (around 2 weeks after the surgery). Monthly plain anteroposterior and bilateral oblique radiographic examinations were performed until 2 years after the index operation. In patients who underwent RHA, trimonthly pelvic CT was performed to evaluate the formation of bony neo-acetabulum. More than 3/4 of circular bony neo-acetabulum formation was defined as complete, and less than 1/2 of a circle as partial (Fig. 1).

At final follow-up, 28 patients were event-free, 6 died of their disease, 5 had no evidence of disease, and 1 was alive with disease. Nine patients (22.5%) developed local recurrence, and their surgical margin status was marginal in 6, wide in 2, and intralesional in 1. Functional results were assessed by the Musculoskeletal Tumor Society (MSTS) system. Scores were recorded at the last visit for patients with intact PPC and who underwent RHA. For PPC reconstruction patients whose graft was removed, the functional scores before and after graft removal were recorded. Final limb length discrepancy on radiographs and the shoe heel height to compensate for limb shortening were recorded. Reconstruction failure was defined as the removal of the composite or iliac wing-femoral head coaptation due to complications. Time to failure (months) was defined as the time elapsed between the first surgery and the date of reconstruction removal. A major complication was defined as the one that eventually necessitated removal of the graft or prosthesis as a revision procedure. A

![Fig. 1. (A) The axial pelvic computed tomography (CT) shows complete bony neo-acetabulum formation 9 months postoperatively. (B) The axial CT shows partial bony neo-acetabulum formation (less than 1/2 of the femoral head circumference).](image-url)
## Table 3. Comparison of Tumor Characteristics and Surgical Outcome between Resection Hip Arthroplasty (n = 24) and Pasteurized Autograft-Prosthesis Composite Reconstruction (n = 16)

| Variable                        | Resection hip arthroplasty (%) | Pasteurized autograft-prosthesis composite reconstruction (%) | p-value |
|---------------------------------|--------------------------------|---------------------------------------------------------------|---------|
| Age (yr) <= 40                  | 14 (58.3)                      | 11 (68.8)                                                    | 0.505   |
| Age (yr) > 40                   | 10 (41.7)                      | 5 (31.2)                                                     |         |
| Sex                             |                                |                                                               | 0.037   |
| Male                            | 17 (70.8)                      | 6 (37.5)                                                     |         |
| Female                          | 7 (29.2)                       | 10 (62.5)                                                    |         |
| Initial tumor volume (cc)       |                                |                                                               |         |
| Mean (range)                    | 226.5 (66–725)                 | 170.6 (26–653)                                               | 0.334   |
| <= 150                          | 12 (50.0)                      | 9 (56.3)                                                     | 0.698   |
| > 150                           | 12 (50.0)                      | 7 (43.7)                                                     |         |
| Resection type                  |                                |                                                               | 0.581   |
| I + II + III                    | 17 (70.8)                      | 10 (62.5)                                                    |         |
| II + III                        | 7 (29.2)                       | 6 (37.5)                                                     |         |
| Surgical time (hr)              |                                |                                                               |         |
| Mean (range)                    | 4.2 (1.7–8.8)                  | 7.2 (5.8–9.3)                                                | <0.001  |
| <= 6                            | 23 (95.8)                      | 1 (6.3)                                                      | <0.001  |
| > 6                             | 1 (4.2)                        | 15 (93.8)                                                    |         |
| Transfusion (pint)              |                                |                                                               |         |
| Mean (range)                    | 6.9 (0–20)                     | 8.7 (4–16)                                                   | 0.219   |
| <= 6                            | 12 (50.0)                      | 4 (25.0)                                                     | 0.114   |
| > 6                             | 12 (50.0)                      | 12 (75.0)                                                    |         |
| Surgical margin                 |                                |                                                               | 0.505   |
| Wide                            | 14 (58.3)                      | 11 (68.8)                                                    |         |
| Marginal, intralesional         | 10 (41.7)                      | 5 (31.2)                                                     |         |
| Major complication              |                                |                                                               | <0.001  |
| Present                         | 0                              | 12 (75.0)                                                    |         |
| Absent                          | 24 (100)                       | 4 (25.0)                                                     |         |
| Minor complication              |                                |                                                               | <0.001  |
| Present                         | 2 (8.3)                        | 15 (6.3)                                                     |         |
| Absent                          | 22 (91.7)                      | 1 (93.7)                                                     |         |
| Final leg length discrepancy (cm)|                                |                                                               |         |
| Mean (range)                    | 3.7 (1.3–6.4)                  | 3.7 (0–7)                                                    | 0.943   |
| <= 3.0                          | 10 (41.7)                      | 6 (37.5)                                                     | 0.792   |
| > 3.0                           | 14 (58.3)                      | 10 (62.5)                                                    |         |
| MSTS score                      |                                |                                                               |         |
| Mean (range)                    | 23.5 (15–28)                   | 14.8 (8–26)                                                  | <0.001  |
| <= 20                           | 6 (25.0)                       | 13 (81.3)                                                    | 0.001   |
| > 20                            | 18 (75.0)                      | 3 (18.8)                                                     |         |
| Local recurrence                |                                |                                                               | 1.000   |
| Recurred                        | 6 (25.0)                       | 4 (25.0)                                                     |         |
| Not recurred                    | 18 (75.0)                      | 12 (75.0)                                                    |         |
| Distant metastasis              |                                |                                                               | 0.407   |
| Occurred                        | 3 (12.5)                       | 4 (25.0)                                                     |         |
| Not occurred                    | 21 (87.5)                      | 12 (75.0)                                                    |         |
| Final outcome                   |                                |                                                               | 0.138   |
| Alive                           | 23 (95.8)                      | 12 (75.0)                                                    |         |
| Dead                            | 1 (4.2)                        | 4 (25.0)                                                     |         |
| Total                           | 24 (100)                       | 16 (100)                                                     |         |

MSTS: Musculoskeletal Tumor Society.
| Case | Major complication | Management of major complication (no. of operations) | Minor complication | Management of minor complication (no. of operations) | Final status (months from index operation to prosthesis removal) | Final LLD (cm) | MSTS score before prosthesis removal | Final MSTS score |
|------|--------------------|------------------------------------------------------|-------------------|-----------------------------------------------------|---------------------------------------------------------------|--------------|-------------------------------------|-----------------|
| 1    | Graft fracture     | Prosthesis removal (1)                               | Infection         | Debridement (1)                                     | Pseudoarthrosis (12)                                           | 4            | 22                                  | 12              |
| 2    | Acetabular cup loosening, graft fracture | Cup revision (1), saddle prosthesis (1) | Infection, proximal migration of saddle prosthesis | Incision and drainage (4)                                   | Saddle prosthesis (125)                                       | 6            | 28                                  | 11              |
| 3    | Graft fracture     | Saddle prosthesis (1)                                | Plate pull out    | Plate removal (1)                                    | Saddle prosthesis (89)                                        | 5            | 24                                  | 9               |
| 4    | Graft fracture, dislocation | Cup revision (1), saddle prosthesis (1) | Saddle mechanism failure | Revision (3)                                           | Saddle prosthesis (98)                                        | 7            | 27                                  | 8               |
| 5    | Infection          | Prosthesis removal (1)                               | Dislocation       | Closed reduction (1)                                 | Pseudoarthrosis (12)                                           | 5            | 19                                  | 15              |
| 6    | Graft fracture     | Prosthesis removal (1)                               | Plate fracture, pin protrusion | Foreign body removal (2)                             | Pseudoarthrosis (62)                                           | 3            | 21                                  | 14              |
| 7    | -                  | -                                                   | Autograft infection | Debridement (1)                                     | Intact                                                        | 0            | -                                   | 15              |
| 8    | Graft fracture     | Prosthesis removal (1)                               | -                 | -                                                   | Pseudoarthrosis (4)                                           | 5            | 18                                  | 18              |
| 9    | Graft resorption, cup loosening | Cup revision (2), bone graft (1), prosthesis removal (1) | Dislocation, infection | Open reduction (2), debridement (2) | Pseudoarthrosis (218)                                         | 6            | 28                                  | 12              |
| 10   | Dislocation        | Cup revision (1)                                     | Dislocation       | Open reduction (3)                                   | Intact                                                        | 0            | -                                   | 26              |
| 11   | Graft fracture     | Prosthesis removal (1)                               | Dislocation       | Open reduction (1)                                   | Pseudoarthrosis (95)                                          | 7            | 26                                  | 14              |
| 12   | -                  | -                                                   | Dislocation       | Open reduction (1)                                   | Intact                                                        | 0            | -                                   | 22              |
| 13   | Infection          | Prosthesis removal (1)                               | -                 | -                                                   | Pseudoarthrosis (1)                                           | 6            | 15                                  | 14              |
| 14   | Nonunion           | Prosthesis removal (1)                               | Wound infection   | Debridement (1)                                     | Pseudoarthrosis (11)                                          | 5            | 19                                  | 9               |
| 15   | -                  | -                                                   | Dislocation       | Open reduction (1)                                   | Intact                                                        | 0            | -                                   | 24              |
| 16   | -                  | -                                                   | -                 | -                                                   | Intact                                                        | 0            | -                                   | 14              |

LLD: limb length discrepancy, MSTS: Musculoskeletal Tumor Society.
| Case | Osteotomy level from iliac crest (cm) | Fixation (femoral head to ilium) | Postoperative immobilization | Bony neo-acetabulum/time to neo-acetabulum formation (mo) | Complication | Limb length discrepancy (cm) | Shoe heel height (cm) | Walking aid | MSTS score |
|------|-------------------------------------|----------------------------------|----------------------------|----------------------------------------------------------|--------------|---------------------------|---------------------|-------------|------------|
| 1    | 10.5                                | None*                            | None                       | Complete/9                                               |              | 2.6                       | None                | None        | 28         |
| 2    | 9                                    | None                            | None                       | Complete/13                                              |              | 3                         | 1                   | None        | 25         |
| 3    | 11                                   | Wire                            | Hip spica cast              | None/NA                                                 |              | 3                         | 1.5                 | None        | 24         |
| 4    | 14.5                                 | None                            | None                       | Partial/8                                                |              | 1.3                       | None                | None        | 28         |
| 5    | 10.7                                 | Wire                            | None                       | Partial/6                                                |              | 3                         | 1.5                 | None        | 25         |
| 6    | 10.7                                 | None                            | None                       | Partial/7                                                | Re-exploration | 3.3                       | 2                   | None        | 25         |
| 7    | 8.2                                  | None                            | None                       | Partial/6                                                |              | 2.4                       | None                | None        | 24         |
| 8    | 9.2                                  | None*                           | None                       | Complete/6                                               |              | 3.1                       | 2                   | None        | 26         |
| 9    | 9.3                                  | Wire*                           | None                       | Partial/7                                                |              | 4.3                       | 3                   | 1 Cane      | 19         |
| 10   | 10                                   | None*                           | None                       | Partial/6                                                |              | 3.5                       | 2                   | None        | 25         |
| 11   | 10                                   | None*                           | None                       | Partial/5                                                | Flap necrosis | 2.4                       | None                | None        | 27         |
| 12   | 9.3                                  | Wire*                           | None                       | Complete/4                                               |              | 2                         | None                | None        | 28         |
| 13   | 10.5                                 | Wire                            | Hip spica cast              | None/NA                                                 |              | 4.7                       | 3                   | 1 Cane      | 19         |
| 14   | 11.2                                 | Wire                            | None                       | Complete/7                                               |              | 4.7                       | 3                   | None        | 25         |
| 15   | 9                                    | Wire*                           | None                       | Complete/6                                               |              | 4.5                       | 3                   | None        | 26         |
| 16   | 9                                    | None                            | None                       | None/NA                                                 |              | 5.8                       | 3                   | 1 Cane      | 19         |
| 17   | 9.4                                  | Wire*                           | None                       | Complete/6                                               |              | 2.5                       | None                | None        | 27         |
| 18   | 9.6                                  | Wire                            | Hip spica cast              | Partial/13                                               |              | 5.2                       | 3                   | None        | 22         |
| 19   | 6.6                                  | Wire*                           | None                       | None/NA                                                 | Chronic pain | 6.4                       | 3                   | 1 Crutch    | 17         |
| 20   | 9                                    | None                            | None                       | None/NA                                                 |              | 6                         | 4                   | 1 Crutch    | 25         |
| 21   | 8.8                                  | Wire*                           | None                       | None/NA                                                 |              | 4.5                       | 3                   | 1 Cane      | 18         |
| 22   | 4                                    | None*                           | None                       | None/NA                                                 |              | 5.5                       | 3                   | 1 Crutch    | 15         |
| 23   | 10                                   | Wire*                           | None                       | Partial/5                                                | Re-exploration | 2.4                       | None                | None        | 24         |
| 24   | 8.8                                  | None                            | None                       | None/NA                                                 |              | 3.7                       | 2                   | None        | 23         |

MSTS: Musculoskeletal Tumor Society, NA: not assessed, Re-exploration: during follow-up, exploration of a lesion suspicious of local recurrence on magnetic resonance imaging turned out to be a new bone in neo-acetabulum formation.
*During surgery, 2 or 3 iliac wing osteotomies were carried out to preserve the iliac crest-hip flexor or abductor muscle continuity.
minor complication was defined as a problem other than those described above, which necessitated an additional surgical procedure or conservative management. Demographic and treatment variables in the 2 study groups were compared using the t-test and Fisher exact test. Analyses were performed using SPSS ver. 13.0 (SPSS Inc., Chicago, IL, USA), and p-values less than 0.05 were considered significant.

RESULTS

Compared to the 16 cases of PPC reconstruction, the 24 cases of RHA showed lower major and minor complication rates (p < 0.001), shorter surgical time (p < 0.001), and superior MSTS score (p < 0.001) (Table 3). No patients who underwent RHA experienced disruption of the femoral head-iliac wing articulation. However, 11 of the 16 PPCs (69%) were removed at an average of 66 months (range, 1 to 218 months). Causes of PPC failure were graft fracture in 8, infection in 2, and nonunion in 1. The 11 failed PPCs were converted to pseudoarthrosis in 8 and a saddle prosthesis in 3. Minor complications in patients who used PPC included wound infection, plate failure, and dislocation. Overall, 16 patients who used PPC underwent 17 major and 24 minor additional procedures after the index operation (Table 4). The average functional score of the 11 failed PPC patients was 22.4 (74%) until removal of the construct, and their average score deteriorated to 12.4 (41%) after removal. Mean leg length discrepancy of the 11 patients with failed PPC was 5.4 cm (range, 3 to 7 cm). One each RHA case showed flap necrosis and chronic pain. Another 2 patients who had RHA underwent re-exploration for suspicious recurrent lesions; however, these proved to be new bones in neo-acetabulum formation.

Of the 24 patients who underwent RHA, circular bony neo-acetabulum on CT was identified in 7 and par-
tial neo-acetabulum in 9; the remaining 8 patients did not show a bony acetabular structure (Table 5). Average time to bony neo-acetabulum formation was 7 months (range, 4 to 13 months) (Fig. 2). Excluding 2 patients who had a hip spica cast postoperatively, all 13 patients with an osteotomy > 9 cm from the iliac crest showed partial or complete bony neo-acetabulum formation, while only 3 of 9 patients with osteotomy level < 9 cm demonstrated bony neo-acetabulum (Fig. 3). The average MSTS functional score in 9 patients with < 9 cm of the remaining iliac wing was 21 (70%), while that of 15 patients with > 9 cm of the ilium was 25 of 30 points (83%). Average limb shortening in 24 patients who underwent RHA was 3.7 cm (range, 1.3 to 6.4 cm).

**DISCUSSION**

Excision of periacetabular tumors usually leaves a large skeletal defect, and attempts at reconstruction by arthrodesis or pseudoarthrosis often result in considerable limb shortening and poor function. In this regard, anatomical reconstruction of the hip and hemipelvis by biological or mechanical means were suggested to provide improved functional outcomes and walking ability. However, most reconstructions had high complication and failure rates. Therefore, a strategy of resection alone has been revisited. In our comparative study of anatomical reconstruction and RHA, we confirmed that RHA is a reliable primary procedure for periacetabular tumors, with low complication rates, good functional results, and short surgical time. Moreover, in patients who underwent RHA, less iliac wing resection and early postoperative mobilization seemed to facilitate early stable bony neo-acetabulum formation.

This study has several limitations. First, there are many confounding factors in relatively small comparative cohort groups. We acknowledge the heterogeneity due to factors such as the amount of bone and soft tissue resection, differences in postoperative management, use of chemotherapy, and the nonrandomized choice of reconstruction type. In addition, because we compared our recent cases of RHA with past PPC reconstruction cases, improvement in surgical skill may have influenced the complication rate. However, between 2 groups, no differences were found in tumor size, pathologic diagnosis, resection type, local recurrence, or metastasis rate. Furthermore, the high proportion of male patients in the RHA group may be related with the superior functional outcome. However, this factor cannot offset the time-related failure pattern in the PPC group.

**Table 6. Comparison with Previous Studies**

| Study                          | No. of patients | Type of pelvic reconstruction (n) | Deep infection (%) | Amputation due to infection (%) | Local recurrence (%) | Mean MSTS score/LLD (cm) |
|-------------------------------|-----------------|---------------------------------|-------------------|-------------------------------|---------------------|--------------------------|
| Current series                | 40              | PPC (16) RHA (24)               | 2/16 (12)         | 0                             | 0                   | 14/3.7/23.5             |
| Hu et al. (2012)              | 27              | RHA                             | 0                 | 0                             | 0                   | 11/6/25                 |
| Angelini et al. (2014)        | 27              | No reconstruction               | 0                 | 0                             | 0                   | 16/7/11/12             |
| Donati et al. (2004)          | 62              | Hip transport                   | 0                 | 0                             | 0                   | 15/3/25                |
| Gebert et al. (2011)          | 20              | No reconstruction               | 0                 | 0                             | 0                   | 6/2/8                  |
| Jaiswal et al. (2008)         | 98              | Pelvic prosthesis               | 0                 | 0                             | 0                   | 17/9/18                |

MSTS: Musculoskeletal Tumor Society; LLD: leg length discrepancy; PPC: pasteurized autograft-prosthesis composite; RHA: resection hip arthroplasty; APC: allograft prosthesis composite; NA: not assessed; TESS: Toronto Extremity Salvage Score.
Our comparative study and previous reports show that RHA is a valuable primary procedure after periacetabular resection, with much reduced complication rates or need for further surgery (Table 6). Chronologically, patients with pelvic resection face 2 major complications: infection and mechanical failure. Infection is a devastating event that may lead to removal of the reconstruction hardware or hindquarter amputation. However, pelvic reconstruction was also reported as an independent contributory factor to infection. Lower rates of infection in the resection alone group may be explained by the shorter operative time, no foreign body, and reduced dead space by permitting proximal migration of the femoral head. Ensuing problems are mechanical, and include nonunion or fracture of biologic material and loosening or breakage of the prosthesis. These late mechanical complications also necessitate the removal of the construct in a substantial proportion of patients, and the functional results of failed cases after intervention are worse than those of primary RHA. Conceptually, because either RHA or failed reconstruction is a pseudoarthrosis, failed reconstruction is assumed to have a functional score similar to that of resection alone. However, 2 factors are related to superior outcome of RHA. One critical factor is the integrity of the femoral head. Patients with failed reconstruction invariably lose the femoral head, and this leads to an additional shortening of around 5 cm (the usual height of the femoral head), compared to RHA patients. Moreover, this loss of femoral head precludes the development of neo-acetabulum. In this regard, in patients who can accept initial shortening of the affected limb, RHA would be a valuable procedure with long-term durability and low risk of complications.

RHA after periacetabular resection is not new. As early as 1978, one study reported the procedure as a satisfactory substitute for hindquarter amputation in 5 patients with chondrosarcoma. Since then, several series have reported the usefulness of RHA after pelvic resection with some variation in technique and concept. However, for better results, there are points to consider with regard to optimal indications, surgical technique, and postoperative care. To create a bony or fibrous “neo hip joint,” the femoral head should not be involved by the tumor and a substantial portion of the iliac wing should be saved. Patients with less iliac wing resection (preferably iliac osteotomy level > 9 cm from the iliac crest) show minimal limb shortening and an increased percentage of bony neo-acetabulum formation. At the time of surgical approach, the origins of hip abductors and hip flexors are detached inferiorly and laterally through osteotomies made along the iliac crest and anterior iliac spine. This approach seems to facilitate repair after resection and functional recovery. To maintain the iliac wing-femoral head contact and to minimize the external rotation of the femoral head, a single wire was tied between the femoral head and ilium in half of our patients. However, as the case number increased, we found that this wire fixation was not necessary. In a previous report, to control the location of the femoral head postoperatively, skin traction with rotation-proof shoes or skeletal traction was applied (ambulation was started 4–6 weeks later). In our series, except for the 3 early cases with postoperative hip spica cast, all patients were encouraged to ambulate around 2 weeks after surgery. Early active exercise seemed to promote the formation of a neo-hip joint. In active young patients, walking without aid and neo-hip joint formation was observed around 6 months postoperatively; however, at older ages, independent walking took up to 1 year. The average MSTS functional score in patients with neo-acetabulum formation was 25.3, while that of patients without neo-acetabulum was 20.1.

In conclusion, our comparative study confirmed that RHA for periacetabular tumors can be an excellent alternative to anatomical reconstruction. RHA offers a short surgical time, low complication rates, and functional results comparable to those of other reconstruction methods. However, this procedure is indicated for patients who can accept some shortening of the limb, and the tumor should be confined to the periacetabular area.

CONFLICT OF INTEREST

No potential conflict of interest relevant to this article was reported.

ACKNOWLEDGEMENTS

The authors thank Ji Young Yoo, MD for radiological evaluation in this study.

REFERENCES

1. Gebert C, Wessling M, Hoffmann C, et al. Hip transposition as a limb salvage procedure following the resection of periacetabular tumors. J Surg Oncol. 2011;103(3):269-75.
2. Steel HH. Partial or complete resection of the hemipelvis:
384

Lee et al. Resection Hip Arthroplasty for Periacetabular Tumors
Clinics in Orthopedic Surgery • Vol. 9, No. 3, 2017 • www.ecios.org

an alternative to hindquarter amputation for periacetabular chondrosarcoma of the pelvis. J Bone Joint Surg Am. 1978;60(6):719-30.

3. Fuchs B, O’Connor MI, Kaufman KR, Padgett DJ, Sim FH. Iliofemoral arthrodesis and pseudarthrosis: a long-term functional outcome evaluation. Clin Orthop Relat Res. 2002;(397):29-35.

4. Aljassir F, Beadel GP, Turcotte RE, et al. Outcome after pelvic sarcoma resection reconstructed with saddle prosthesis. Clin Orthop Relat Res. 2005;438:36-41.

5. Satcher Jr RL, O’Donnell RJ, Johnston JO. Reconstruction of the pelvis after resection of tumors about the acetabulum. Clin Orthop Relat Res. 2003;(409):209-17.

6. Guo W, Li D, Tang X, Ji T. Surgical treatment of pelvic chondrosarcoma involving periacetabulum. J Surg Oncol. 2010;101(2):160-5.

7. Jaiswal PK, Aston WJ, Grimer RJ, et al. Peri-acetabular resection and endoprosthetic reconstruction for tumours of the acetabulum. J Bone Joint Surg Br. 2008;90(9):1222-7.

8. Tsuchiya H, Wan SL, Sakayama K, Yamamoto N, Nishida H, Tomita K. Reconstruction using an autograft containing tumour treated by liquid nitrogen. J Bone Joint Surg Br. 2005;87(2):218-25.

9. Jeon DG, Kim MS, Cho WH, Song WS, Lee SY. Reconstruction with pasteurized autograft-total hip prosthesis composite for periacetabular tumors. J Surg Oncol. 2007;96(6):493-502.

10. Langlais F, Lambotte JC, Thomazeau H. Long-term results of hemipelvis reconstruction with allografts. Clin Orthop Relat Res. 2001;(388):178-86.

11. Donati D, Di Bella C, Frisoni T, Cevolani L, DeGroot H. Alloprosthetic composite is a suitable reconstruction after periacetabular tumor resection. Clin Orthop Relat Res. 2011;469(5):1450-8.

12. Enneking WF, Dunham WK. Resection and reconstruction for primary neoplasms involving the innominate bone. J Bone Joint Surg Am. 1978;60(6):731-46.

13. Aboulafia AJ, Buch R, Mathews J, Li W, Malawer MM. Reconstruction using the saddle prosthesis following excision of primary and metastatic periacetabular tumors. Clin Orthop Relat Res. 1995;(314):203-13.

14. Bell RS, Davis AM, Wunder JS, Buconjic T, McGoveran B, Gross AE. Allograft reconstruction of the acetabulum after resection of stage-IIB sarcoma: intermediate-term results. J Bone Joint Surg Am. 1997;79(11):1663-74.

15. Delloye C, Banse X, Brichard B, Docquier PL, Cornu O. Pelvic reconstruction with a structural pelvic allograft after resection of a malignant bone tumor. J Bone Joint Surg Am. 2007;89(3):579-87.

16. Ozaki T, Hoffmann C, Hillmann A, Gosheger G, Lindner N, Winkelmann W. Implantation of hemipelvis prosthesis after resection of sarcoma. Clin Orthop Relat Res. 2002;(396):197-205.

17. Abudu A, Grimer RJ, Cannon SR, Carter SR, Sneath RS. Reconstruction of the hemipelvis after the excision of malignant tumours: complications and functional outcome of prostheses. J Bone Joint Surg Br. 1997;79(5):773-9.

18. Hillmann A, Hoffmann C, Gosheger G, Rodl R, Winkelmann W, Ozaki T. Tumors of the pelvis: complications after reconstruction. Arch Orthop Trauma Surg. 2003;123(7):340-4.

19. Ozaki T, Hillmann A, Bettin D, Wuisman P, Winkelmann W. High complication rates with pelvic allografts: experience of 22 sarcoma resections. Acta Orthop Scand. 1996;67(4):333-8.

20. Hoffmann C, Gosheger G, Gebert C, Jurgens H, Winkelmann W. Functional results and quality of life after treatment of pelvic sarcomas involving the acetabulum. J Bone Joint Surg Am. 2006;88(3):575-82.

21. Griesser MJ, Gillette B, Crist M, et al. Internal and external hemipelvectomy or flail hip in patients with sarcomas: quality-of-life and functional outcomes. Am J Phys Med Rehabil. 2012;91(1):24-32.

22. Kusuzaki K, Shinjo H, Kim W, Nakamura S, Murata H, Hirasawa Y. Resection hip arthroplasty for malignant pelvic tumor: outcome in 5 patients followed more than 2 years. Acta Orthop Scand. 1998;69(6):617-21.

23. Hu YC, Huang HC, Lun DX, Wang H. Resection hip arthroplasty as a feasible surgical procedure for periacetabular tumors of the pelvis. Eur J Surg Oncol. 2012;38(8):692-9.

24. Enneking WF, Spanier SS, Goodman MA. A system for the surgical staging of musculoskeletal sarcoma. Clin Orthop Relat Res. 1980;(153):106-20.

25. Bieling P, Rehan N, Winkler P, et al. Tumor size and prognosis in aggressively treated osteosarcoma. J Clin Oncol. 1996;14(3):848-58.

26. Enneking WF, Dunham W, Gebhardt MC, Malawar M, Pritchard DJ. A system for the functional evaluation of reconstructive procedures after surgical treatment of tumors of the musculoskeletal system. Clin Orthop Relat Res. 1993;(286):241-6.

27. Guo W, Li D, Tang X, Yang Y, Ji T. Reconstruction with modular hemipelvic prostheses for periacetabular tumor. Clin Orthop Relat Res. 2007;461:180-8.

28. Angelini A, Drago G, Tovarelli G, Calabro T, Ruggieri P. Infection after surgical resection for pelvic bone tumors: an analysis of 270 patients from one institution. Clin Orthop Relat Res. 2014;472(1):349-59.
29. Ueda T, Kakunaga S, Takenaka S, Araki N, Yoshikawa H. Constrained total hip megaprostheses for primary periacetabular tumors. Clin Orthop Relat Res. 2013;471(3):741-9.

30. Carmody Soni EE, Miller BJ, Scarborough MT, Parker Gibbs C. Functional outcomes and gait analysis of patients after periacetabular sarcoma resection with and without ischiofemoral arthrodesis. J Surg Oncol. 2012;106(7):844-9.